Open AccessJournal Article
1F7, A novel cell surface molecule, involved in helper function of CD4 cells
Chikao Morimoto,Y Torimoto,G Levinson,Christopher E. Rudd,M Schrieber,Nam H. Dang,Norman L. Letvin,Stuart F. Schlossman +7 more
204
TL;DR: A monoclonal antibody is developed that inhibits soluble Ag-driven T cell proliferation as well as PWM-driven IgG synthesis and includes molecules distinct from Ta1, an activation Ag on T cells.
read more
Abstract: We have developed a monoclonal antibody, anti-1F7, that inhibits soluble Ag-driven T cell proliferation as well as PWM-driven IgG synthesis. Anti-1F7 antibody reacts with approximately 57% of unfractionated T cells, 62% of CD4+ cells, and 54% of CD8+ cells. Although the 1F7 Ag is widely distributed among lymphoid cells, this Ag on CD4+ cells is preferentially expressed on the CDw29(4B4+) helper population. Moreover, anti-1F7 antibody further subdivides the CD4+CDw29+ cell subset into CDw29+1F7+ and CDw29+1F7- populations. The CD4+CDw29+1F7+ population of cells maximally proliferates to recall Ag such as tetanus toxoid, whereas helper function for PWM-driven IgG synthesis by B cells belongs to both the CD4+CDw29+1F7+ and CD4+CDw29+1F7- population of cells. The most prominent structure defined by this antibody is a 110-kDa molecule that is different from the 135-kDa, 160-kDa, and 185-kDa glycoproteins identified by anti-CDw29 antibody and the 180-kDa glycoprotein identified by UCHL-1 antibody. It is, however, related to the molecule recognized by anti-Ta1, an activation Ag on T cells. Furthermore, although the Ta1 molecule is recognized by anti-1F7 mAb, the 1F7 family of structures also includes molecules distinct from Ta1.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
•Journal Article
Roxithromycin specifically inhibits development of collagen induced arthritis and production of proinflammatory cytokines by human T cells and macrophages.
Yasuyo Urasaki,Mamoru Nori,Satoshi Iwata,Takahiro Sasaki,Osamu Hosono,Hiroshi Kawasaki,Hirotoshi Tanaka,Nam H. Dang,Eiji Ikeda,Chikao Morimoto +9 more
TL;DR: RXM treatment of mice with CIA reduced the severity of arthritis and serum level of IL-6, as well as leukocyte migration into the affected joints and destruction of bones and cartilage, suggesting that RXM may be useful for the therapy of rheumatoid arthritis as wellAs other inflammatory diseases such as Crohn's disease.
20
A Raf-1-related p110 polypeptide associates with the CD4-p56lck complex in T cells.
TL;DR: The detection of an additional 110-kDa polypeptide (p110) associated with the CD4-p56lck complex in human peripheral blood T lymphocytes and leukemic T-cell lines was reported in this article.
20
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
TL;DR: The identification of CD26 expression on human osteoclasts and demonstrated that humanized IgG1 monoclonal antibody targeting CD26, huCD26mAb, inhibits human OC differentiation suggest that CD26 is a potential target molecule in MM and that hu CD26m Ab could act as a therapeutic agent.
Influence of CD26 and integrins on the antigen sensitivity of human memory T cells
Fiorenza Falcioni,Himanshu Shah,Damir Vidovic,Chikao Morimoto,Charles Belunis,David Robert Bolin,Zoltan A. Nagy +6 more
TL;DR: It is suggested that increasing the antigen sensitivity via antigen-nonspecific molecules is a physiologic mechanism for maintaining T-cell memory in face of decreasing antigen concentration, and for ensuring preferential activation of memory T cells upon repeated encounter with antigen.
19